Revolutionising healthcare with peptide-based therapies

ImmuPharma is a biopharmaceutical company that specializes in the usage and development of biopolymers, specifically peptides.

Peptides are naturally occurring biological molecules and represent a distinctive class of pharmaceutical therapeutics, uniquely positioned between small molecules and proteins, yet biochemically and therapeutically distinct from both.

We are dedicated to developing an innovative portfolio of peptide-based therapeutic drugs with a focus on Autoimmunity/Inflammation and Anti-Infectives.

In summary:

  • Developing clinical programs for P140 in Phase 3 for Systemic Lupus Erythematosus (SLE) (Lupuzor™) and P140 in a pivotal Phase 2/3 for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
  • Advancing preclinical programs using our proprietary technology to program the ADMET properties of peptides, as well as small molecules with bioavailability limitations
  • Unlocking value through strategic licensing, partnerships, and collaborations
  • Creating near-term shareholder value with our late stage, lead asset, P140 and providing significant opportunities throughout our pipeline

Our pipeline

Lupuzor™ Lupus
P140 CIDP*
P140 other indications

*Phase 2/3 adaptive trial becomes a pivotal trial for filing

BioAMB Fungal infections
BioCIN Bacterial infections

Key progress

Share Price

Market Cap

Market Commentary